Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2223 plus Penpulimab in Advanced Cancers
NCT05894421Phase 1Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2023
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bemipalimab in cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Started Jun 2023; status: recruiting.
02
Drugs
bemipalimab
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05894421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05894421.